ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

14 links0 made here, not in the record27 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05203172The FLOTILLA Study:Providing Continued Accessto The Study MedicinesEncorafenib and Binimetinibfor Participants in PriorClinical TrialsPfizerPhase 4 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 2 · ClinicalTrials.gov record · Version of 2026-10-02Oct 19 · ClinicalTrials.gov record · Version of 2026-10-19Version of 2026-10-19CONDITIONSSolid TumorsNo longer in the registry's filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSBinimetinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEncorafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedVemurafenibIntervention entry›Nov 2 · Claude Opus 5.5 · UnclearNov 18 · Rule based · BackgroundUnclearRibociclibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · BackgroundBackground · establishedCetuximabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · BackgroundBackground · establishedFluorouracilEntry “5-Fluorouracil”, read by our n…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundLeucovorinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundOxaliplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundIrinotecanIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundBevacizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Binimetinib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Binimetinib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 2The record itselfClinicalTrials.gov recordVersion of 2026-10-02Record change
Oct 19The record itselfClinicalTrials.gov recordVersion of 2026-10-19Record change
Nov 2BinimetinibClaude Opus 5.5TestedCurrent
Nov 2EncorafenibClaude Opus 5.5TestedCurrent
Nov 2VemurafenibClaude Opus 5.5UnclearCurrent
Nov 2RibociclibClaude Opus 5.5Background · establishedCurrent
Nov 2CetuximabClaude Opus 5.5BackgroundCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · establishedCurrent
Nov 2FluorouracilClaude Opus 5.5BackgroundCurrent
Nov 2LeucovorinClaude Opus 5.5BackgroundCurrent
Nov 2OxaliplatinClaude Opus 5.5BackgroundCurrent
Nov 2IrinotecanClaude Opus 5.5BackgroundCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2BevacizumabClaude Opus 5.5BackgroundCurrent
Nov 14Solid TumorsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18BinimetinibRule based · role ruleTestedAgrees
Nov 18EncorafenibRule based · role ruleTestedAgrees
Nov 18VemurafenibRule based · role ruleBackgroundOverridden
Nov 18RibociclibRule based · role ruleBackgroundAgrees
Nov 18CetuximabRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18FluorouracilRule based · role ruleBackgroundAgrees
Nov 18LeucovorinRule based · role ruleBackgroundAgrees
Nov 18OxaliplatinRule based · role ruleBackgroundAgrees
Nov 18IrinotecanRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.